Assessment of liver function in patients with type 2 diabetes receiving ertugliflozin

被引：0
|
作者：
Gallo, S. [1 ]
Calle, R. A. [2 ]
Terra, S. G. [3 ]
Pong, A. [4 ]
Tarasenko, L. [5 ]
Raji, A. [4 ]
机构：
[1] Pfizer Pharma GmbH, Berlin, Germany
[2] Pfizer Inc, Cambridge, MA USA
[3] Pfizer Inc, Andover, MA USA
[4] Merck & Co Inc, Kenilworth, NJ USA
[5] Pfizer Inc, New York, NY USA
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
712
引用
收藏
页码：S341 / S341
页数：1
相关论文
共 50 条
  • [1] ASSESSMENT OF LIVER FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS RECEIVING ERTUGLIFLOZIN
    Gallo, Silvina
    Calle, Roberto
    Terra, Steven
    Pong, Annpey
    Tarasenko, Lisa
    Raji, Annaswamy
    [J]. HEPATOLOGY, 2019, 70 : 1261A - 1261A
  • [2] Assessment of adverse renal effects in patients with type 2 diabetes receiving ertugliflozin
    Terra, S. G.
    Patel, S.
    Hickman, A.
    Frederich, R.
    Lauring, B.
    Johnson, S.
    Huyck, S.
    Mancuso, J. P.
    [J]. DIABETOLOGIA, 2018, 61 : S300 - S301
  • [3] Assessment of Adverse Renal Effects in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin
    Patel, Shrita M.
    Hickman, Mary A.
    Frederich, Robert
    Lauring, Brett
    Terra, Steven
    Johnson, Susan L.
    Huyck, Susan
    Mancuso, James P.
    [J]. DIABETES, 2018, 67
  • [4] Ertugliflozin for Type 2 Diabetes
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2018, 60 (1545): : 70 - 72
  • [5] Ertugliflozin for Type 2 Diabetes
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (23): : 2434 - 2435
  • [6] Ertugliflozin for treatment of patients with Type 2 diabetes mellitus
    Yang, Junyi
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (08) : 747 - 753
  • [7] Incidence of urinary tract infections in patients with type 2 diabetes receiving ertugliflozin, placebo or active comparator
    Hickman, M. A.
    Patel, S.
    Lauring, B.
    Terra, S. G.
    Johnson, S.
    Huyck, S.
    Mancuso, J. P.
    [J]. DIABETOLOGIA, 2018, 61 : S306 - S306
  • [8] Evaluation of fractures, bone mineral density and bone biomarkers in patients with type 2 diabetes receiving ertugliflozin
    Masiukiewicz, U.
    Hickman, A.
    Frederich, R.
    Patel, S.
    Gallo, S.
    Lauring, B.
    Terra, S. G.
    Johnson, S.
    Huyck, S.
    Mancuso, J. P.
    [J]. DIABETOLOGIA, 2018, 61 : S306 - S307
  • [9] Ertugliflozin for the treatment of type 2 diabetes
    Sharma, R.
    Razdan, K.
    Kuhad, A.
    Kuhad, A.
    [J]. DRUGS OF TODAY, 2019, 55 (03) : 167 - 175
  • [10] Liver function in the patients with diabetes mellitus type 2
    Alibasic, Esad
    Ljuca, Farid
    Nuhbegovic, Sabina
    Zildzic, Muharem
    Poljakovic, Dzemal
    [J]. HEALTHMED, 2008, 2 (02): : 89 - 94
12345